Report Overview

The UK Lysosomal Storage Disorders Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

LSDs usually is caused by a deficiency of a single lysosomal enzyme or protein, which results in a build-up of lipid or sugar in the lysosome. There are many lysosomal enzymes and they each work in sequence with each other to break down lipids and sugars into simpler forms for removal from the cell. A deficiency in the function of one enzyme means that the process of breaking down and recycling lipids and sugars stops, and they remain stored in the lysosomes of each cell. This affects normal cell function.

There are nearly 50 of these disorders altogether, and they may affect different parts of the body, including the skeleton, brain, skin, heart, and central nervous system. According to NHS Foundation Trust, the incidence is approximately 1 in 7,000 births. Although affected children usually appear normal at birth, each disorder progressively develops symptoms, which can include bone and skeletal deformity, visual and hearing problems, enlarged head and tongue, coarse hair, developmental delays, and reduction over time of the mental function. One of the main objectives of the service is to increase the benefits of treatment for patients with LSDs with particular reference to the use of enzyme replacement therapy.

The types of lysosomal storage disorders that occur most often in babies and children include Gaucher Disease (Types I, II, and III), Batten Disease, Cystinosis, Fabry Disease, Pompe Disease, Aspartylglucosaminuria, Niemann Pick Disease, and Tay Sachs Disease.



Market Growth Drivers

An increasing diagnosis rate due to growing public awareness and financial incentives for orphan drug development to recover R&D costs is the primary factor fuelling the growth of the LSD therapeutics market. Also, an increasing focus of major biopharmaceutical companies on the research and development of drugs for the treatment of lysosomal storage disorders is expected to boost the LSD therapeutics market growth during the forecast period.

Moreover, the number of treatment options currently in the pipeline is further expected to bolster the revenue growth of the LSD therapeutics market over the forecast period. The advent of therapies targeting neuropathic manifestations by crossing the blood-brain barrier (BBB) and therapies that overcome immune response and have better tissue selectivity has also been anticipated to fuel the LSD therapeutics market growth in the upcoming years.

Market Restraints

However, the UK LSD therapeutics market also faces a few restraints that include heterogeneity of the disease leading to underdiagnoses of lysosomal storage disorders, lack of treatment options, expensive drugs, change in payer policies, lack of proper training and knowledge, nature of the disease, and concerns in diagnosis. The restraints can be overcome by the drugs that aid in improving the lifespan and quality of life for the patients.